ID   HT-1080
AC   CVCL_0317
SY   Ht-1080; HT 1080; HT1080; HT 1080.T
DR   BTO; BTO:0001282
DR   CLO; CLO_0004266
DR   CLO; CLO_0004276
DR   EFO; EFO_0002059
DR   MCCL; MCC:0000210
DR   CLDB; cl1735
DR   CLDB; cl1736
DR   CLDB; cl1737
DR   CLDB; cl1738
DR   CLDB; cl1740
DR   CLDB; cl1741
DR   CLDB; cl1742
DR   CLDB; cl4913
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-121
DR   ATCC; CRL-7951
DR   BCRC; 60037
DR   BCRJ; 0110
DR   BioGRID_ORCS_Cell_line; 279
DR   BioSample; SAMN01821563
DR   BioSample; SAMN01821634
DR   BioSample; SAMN01821685
DR   BioSample; SAMN01821731
DR   BioSample; SAMN03471913
DR   BioSample; SAMN10987635
DR   cancercelllines; CVCL_0317
DR   CCRID; 1101HUM-PUMC000070
DR   CCRID; 3101HUMTCHu170
DR   CCRID; 4201HUM-CCTCC00105
DR   Cell_Model_Passport; SIDM00828
DR   ChEMBL-Cells; CHEMBL3308396
DR   ChEMBL-Targets; CHEMBL614580
DR   CLS; 300216
DR   Cosmic; 716177
DR   Cosmic; 716188
DR   Cosmic; 724819
DR   Cosmic; 907064
DR   Cosmic; 912000
DR   Cosmic; 1045409
DR   Cosmic; 1067221
DR   Cosmic; 1933190
DR   Cosmic; 2009505
DR   Cosmic; 2301553
DR   Cosmic; 2307731
DR   Cosmic; 2560245
DR   Cosmic; 2764533
DR   Cosmic-CLP; 907064
DR   DepMap; ACH-000054
DR   DSMZ; ACC-315
DR   DSMZCellDive; ACC-315
DR   ECACC; 85111505
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 907064
DR   GEO; GSM185089
DR   GEO; GSM185090
DR   GEO; GSM256074
DR   GEO; GSM256075
DR   GEO; GSM256076
DR   GEO; GSM256077
DR   GEO; GSM256078
DR   GEO; GSM256079
DR   GEO; GSM256080
DR   GEO; GSM256081
DR   GEO; GSM256082
DR   GEO; GSM256083
DR   GEO; GSM256084
DR   GEO; GSM256085
DR   GEO; GSM256086
DR   GEO; GSM256087
DR   GEO; GSM256088
DR   GEO; GSM256089
DR   GEO; GSM256090
DR   GEO; GSM256091
DR   GEO; GSM256092
DR   GEO; GSM256093
DR   GEO; GSM256094
DR   GEO; GSM256095
DR   GEO; GSM256096
DR   GEO; GSM256097
DR   GEO; GSM256098
DR   GEO; GSM256099
DR   GEO; GSM256100
DR   GEO; GSM256101
DR   GEO; GSM256102
DR   GEO; GSM256103
DR   GEO; GSM256104
DR   GEO; GSM256105
DR   GEO; GSM256106
DR   GEO; GSM256107
DR   GEO; GSM256108
DR   GEO; GSM256109
DR   GEO; GSM256110
DR   GEO; GSM256111
DR   GEO; GSM256112
DR   GEO; GSM256113
DR   GEO; GSM256114
DR   GEO; GSM827307
DR   GEO; GSM887136
DR   GEO; GSM888207
DR   GEO; GSM1669908
DR   GEO; GSM1676302
DR   GEO; GSM1701637
DR   GEO; GSM3585511
DR   GEO; GSM3585512
DR   GEO; GSM3585513
DR   GEO; GSM3585514
DR   IARC_TP53; 21378
DR   IBRC; C10104
DR   ICLC; HTL98016
DR   IGRhCellID; HT1080
DR   JCRB; IFO50354
DR   KCB; KCB 2013029YJ
DR   KCLB; 10121
DR   LiGeA; CCLE_463
DR   Lonza; 744
DR   NCBI_Iran; C437
DR   PharmacoDB; HT1080_625_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0317
DR   PubChem_Cell_line; CVCL_0317
DR   RCB; RCB1956
DR   TKG; TKG 0202
DR   TOKU-E; 1963
DR   Wikidata; Q5636047
RX   CelloPub=CLPUB00698;
RX   PubMed=375235;
RX   PubMed=3335022;
RX   PubMed=3413074;
RX   PubMed=3558490;
RX   PubMed=3986962;
RX   PubMed=4132053;
RX   PubMed=6538202;
RX   PubMed=6652615;
RX   PubMed=11416159;
RX   PubMed=11668190;
RX   PubMed=12068308;
RX   PubMed=17254797;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22282976;
RX   PubMed=22460905;
RX   PubMed=24726063;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26351324;
RX   PubMed=26368816;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Doubling time: 26 hours (PubMed=4132053); ~30 hours (DSMZ=ACC-315).
CC   HLA typing: A*31:01,68:01; B*27:05,27:05; C*02:02,02:02 (PubMed=26589293).
CC   HLA typing: A*31:01:02,68:01:01; B*27:05:02; C*02:02:02; DPB1*03:01,04:01; DQA1*03:03:01,05:01:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,04:07:01 (CLS=300216).
CC   HLA typing: A*31:01:02,68:01:01; B*27:05:02,27:05:02; C*02:02:02,02:02:02; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DRA*01:01:01,01:02:02 (DSMZCellDive=ACC-315).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC).
CC   Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (PubMed=26368816).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.86%; Native American=0.35%; East Asian, North=1.36%; East Asian, South=0.29%; South Asian=0%; European, North=68.21%; European, South=28.94% (PubMed=30894373).
CC   Misspelling: HT1180; Note=Occasionally.
CC   Discontinued: ATCC; CRL-7951; true.
CC   Discontinued: RCB; RCB1956; true.
CC   Derived from site: In situ; Bone, pelvis, acetabulum; UBERON=UBERON_0001269.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; CelloPub=CLPUB00698; PubMed=11416159; PubMed=17254797; PubMed=25877200; RCB
ST   Amelogenin: X,Y
ST   CSF1PO: 11 (PubMed=17254797)
ST   CSF1PO: 12 (ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=25877200; RCB)
ST   D13S317: 12,14
ST   D16S539: 9,12
ST   D18S51: 12,18
ST   D19S433: 13.2,15 (CCRID)
ST   D19S433: 14,15 (DSMZ)
ST   D21S11: 28,30
ST   D2S1338: 25,26
ST   D3S1358: 16
ST   D5S818: 11,13
ST   D7S820: 9,10
ST   D8S1179: 13,14
ST   FGA: 22,25
ST   Penta D: 9,12
ST   Penta E: 5,15
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 14,19
DI   NCIt; C3043; Fibrosarcoma
DI   ORDO; Orphanet_2030; Fibrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 46
RX   CelloPub=CLPUB00698;
RA   van Bokhoven A.;
RT   "Models for prostate cancer. Molecular characterization and critical
RT   appraisal of human prostate carcinoma cell lines.";
RL   Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands.
RX   PubMed=375235; DOI=10.1073/pnas.76.3.1288;
RA   Sherwin S.A., Sliski A.H., Todaro G.J.;
RT   "Human melanoma cells have both nerve growth factor and nerve growth
RT   factor-specific receptors on their cell surfaces.";
RL   Proc. Natl. Acad. Sci. U.S.A. 76:1288-1292(1979).
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
RX   PubMed=3413074; DOI=10.1073/pnas.85.16.6042;
RA   Pereira-Smith O.M., Smith J.R.;
RT   "Genetic analysis of indefinite division in human cells:
RT   identification of four complementation groups.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988).
RX   PubMed=3558490; DOI=10.1002/jcp.1041300303;
RA   Gupta R.S., Dudani A.K.;
RT   "Species-specific differences in the toxicity of rhodamine 123 towards
RT   cultured mammalian cells.";
RL   J. Cell. Physiol. 130:321-327(1987).
RX   PubMed=3986962; DOI=10.1093/carcin/6.4.549;
RA   Watatani M., Ikenaga M., Hatanaka T., Kinuta M., Takai S.-i., Mori T.,
RA   Kondo S.;
RT   "Analysis of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced DNA
RT   damage in tumor cell strains from Japanese patients and demonstration
RT   of MNNG hypersensitivity of Mer xenografts in athymic nude mice.";
RL   Carcinogenesis 6:549-553(1985).
RX   PubMed=4132053; DOI=10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z;
RA   Rasheed S., Nelson-Rees W.A., Toth E.M., Arnstein P., Gardner M.B.;
RT   "Characterization of a newly derived human sarcoma cell line (HT-1080).";
RL   Cancer 33:1027-1033(1974).
RX   PubMed=6538202; DOI=10.1083/jcb.98.3.1133;
RA   Azzarone B., Suarez H., Mingari M.C., Moretta L., Fauci A.S.;
RT   "4F2 monoclonal antibody recognizes a surface antigen on spread human
RT   fibroblasts of embryonic but not of adult origin.";
RL   J. Cell Biol. 98:1133-1137(1984).
RX   PubMed=6652615; DOI=10.1016/0165-4608(83)90092-4;
RA   Chen T.-R., Hay R.J., Macy M.L.;
RT   "Intercellular karyotypic similarity in near-diploid cell lines of
RT   human tumor origins.";
RL   Cancer Genet. Cytogenet. 10:351-362(1983).
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001;
RA   Azari S., Ahmadi N., Tehrani M.J., Shokri F.;
RT   "Profiling and authentication of human cell lines using short tandem
RT   repeat (STR) loci: report from the National Cell Bank of Iran.";
RL   Biologicals 35:195-202(2007).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=24726063; DOI=10.1186/1756-9966-33-33;
RA   Koelsche C., Renner M., Hartmann W., Brandt R., Lehner B.,
RA   Waldburger N., Alldinger I., Schmitt T., Egerer G., Penzel R.,
RA   Wardelmann E., Schirmacher P., von Deimling A., Mechtersheimer G.;
RT   "TERT promoter hotspot mutations are recurrent in myxoid liposarcomas
RT   but rare in other soft tissue sarcoma entities.";
RL   J. Exp. Clin. Cancer Res. 33:33.1-33.8(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
RX   PubMed=26368816; DOI=10.1371/journal.pone.0133813;
RA   Li L.-Y., Paz A.C., Wilky B.A., Johnson B., Galoian K., Rosenberg A.,
RA   Hu G.-Z., Tinoco G., Bodamer O.A., Trent J.C. II;
RT   "Treatment with a small molecule mutant IDH1 inhibitor suppresses
RT   tumorigenic activity and decreases production of the oncometabolite
RT   2-hydroxyglutarate in human chondrosarcoma cells.";
RL   PLoS ONE 10:E0133813-E0133813(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).